zolbetuximab
astellas
[]
kicking off oral abstract session #gi23 with results from spotlight testing addition of zolbetuximab to mfolfox6 in advanced/metastatic gastric or gej adenoca (cldn18.2+/her2-). primary endpoint pfs met 
Fellow @PennCancer. @NIH_LRP.  @PC3Innovation. MSCE Student. GI Cancers. Former @UTSWIMchief. Lucas’ dad forever. Views own. ASCO FCOI https://t.co/rmHB23k0Ph